Clinical Study Results
In female patients with 'high-risk' breast cancer, coenzyme Q10 supplementation can improve the chance of survival (i.e. prognosis).
The effects of coenzyme Q10 supplementation was studied in a clinical study of 32 patients assessed to have ‘high-risk’ breast cancer. In this study, patients were treated with antioxidants, fatty acids, and coenzyme Q10. A brief overview of the findings:
- 6 patients showed partial tumor regression on 90 mg of coenzyme Q10 supplementation.
- In one of these 6 cases, where the dose was increased to 390 mg of coenzyme Q10, the tumor was no longer perceptible after a month – and mammography confirmed tumor absence in a month afterward.
- Another patient treated with 300 mg of coenzyme Q10 daily showed no residual tumor in the tumor bed after 3 months.
In patients with AIDS or AIDS-related complex (ARC), coenzyme Q10 supplementation can reduce opportunistic infection risks – boosting survival rates.
The effects of coenzyme Q10 supplementation was studied in a clinical study of 7 patients with AIDS or ARC. In this study:
- Coenzyme Q10 supplementation helped strengthen patients’ immune system response*.
- Coenzyme Q10 supplementation improved the symptoms of 5 patients, with no opportunistic infection after 4 – 7 months.
*Measured by an improvement in the relationship between T4-helpers and T8-suppressor cells.
In healthy persons, selenium supplementation – administered as oral sodium selenite – can boost the immune system response.
The effects of selenium supplementation were studied in a clinical study of 39 healthy persons.
In this study, researchers assessed immune cells' gene expression before and after 6-week supplementation with 100 μg Se/d as sodium selenite. A brief overview of the findings:
- Selenium supplementation increased participants’ plasma selenium concentration by an average of 19%.
- Selenium supplementation increased the gene expression of proteins involved in protein biosynthesis – supporting and improving the immune system’s function.